Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors

Author： Spraggs Colin F   Xu Chun-Fang   Hunt Christine M  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.5, 2013-04, pp. : 541-554

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology

By  

Current Drug Metabolism, Vol. 18, Iss. 3, 2017-03 ,pp. : 186-198

Bentham Science Publishers

Access to resources Recommend Favorite

Selective tyrosine kinase inhibitors

By Wilkinson S.E.   Harris W.  

Expert Opinion on Emerging Drugs, Vol. 5, Iss. 3, 2000-10 ,pp. : 287-297

Informa Healthcare

Access to resources Recommend Favorite

Tyrosine Kinase Inhibitors

By  

Current Cancer Drug Targets, Vol. 10, Iss. 5, 2010-08 ,pp. : 462-483

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on 4-Anilinoquinazolines

By Scheffler Matthias  

Clinical Pharmacokinetics, Vol. 50, Iss. 6, 2011-06 ,pp. : 371-403

Adis International

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on Pyrimidines, Pyridines and Pyrroles

By >  

Clinical Pharmacokinetics, Vol. 50, Iss. 9, 2011-09 ,pp. : 551-603

Adis International

Access to resources Recommend Favorite